HK1062895A1 - Combination comprising N-ä5-Ä4-(4-methyl-piperazino-methyl)-benzoylamidoÜ-2-methylphenylü-4-(3-pyridyl)-2pyrimidine-amine and a biphosphonate - Google Patents

Combination comprising N-ä5-Ä4-(4-methyl-piperazino-methyl)-benzoylamidoÜ-2-methylphenylü-4-(3-pyridyl)-2pyrimidine-amine and a biphosphonate

Info

Publication number
HK1062895A1
HK1062895A1 HK04105830A HK04105830A HK1062895A1 HK 1062895 A1 HK1062895 A1 HK 1062895A1 HK 04105830 A HK04105830 A HK 04105830A HK 04105830 A HK04105830 A HK 04105830A HK 1062895 A1 HK1062895 A1 HK 1062895A1
Authority
HK
Hong Kong
Prior art keywords
methyl
combination
piperazino
pyridyl
amine
Prior art date
Application number
HK04105830A
Other languages
English (en)
Inventor
Christian Bruns
Elisabeth Buchdunger
Terence O'reilly
Sandra Leta Silberman
Markus Wartmann
Gisbert Weckbecker
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1062895A1 publication Critical patent/HK1062895A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
HK04105830A 2001-05-16 2004-08-05 Combination comprising N-ä5-Ä4-(4-methyl-piperazino-methyl)-benzoylamidoÜ-2-methylphenylü-4-(3-pyridyl)-2pyrimidine-amine and a biphosphonate HK1062895A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29142701P 2001-05-16 2001-05-16
PCT/EP2002/005362 WO2002092091A1 (en) 2001-05-16 2002-05-15 Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent

Publications (1)

Publication Number Publication Date
HK1062895A1 true HK1062895A1 (en) 2004-12-03

Family

ID=23120246

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04105830A HK1062895A1 (en) 2001-05-16 2004-08-05 Combination comprising N-ä5-Ä4-(4-methyl-piperazino-methyl)-benzoylamidoÜ-2-methylphenylü-4-(3-pyridyl)-2pyrimidine-amine and a biphosphonate

Country Status (28)

Country Link
US (3) US20040167134A1 (zh)
EP (2) EP1392313B1 (zh)
JP (2) JP4477303B2 (zh)
KR (2) KR20030094415A (zh)
CN (1) CN1700917B (zh)
AT (1) ATE359790T1 (zh)
AU (1) AU2002342335B2 (zh)
BR (1) BR0209647A (zh)
CA (1) CA2444867C (zh)
CO (1) CO5540315A2 (zh)
CZ (1) CZ299756B6 (zh)
DE (1) DE60219617T2 (zh)
DK (1) DK1392313T3 (zh)
EC (1) ECSP034823A (zh)
ES (1) ES2283570T3 (zh)
HK (1) HK1062895A1 (zh)
HU (1) HUP0400038A3 (zh)
IL (1) IL158274A0 (zh)
MX (1) MXPA03010401A (zh)
NO (2) NO325453B1 (zh)
NZ (1) NZ529145A (zh)
PL (2) PL392652A1 (zh)
PT (1) PT1392313E (zh)
RU (1) RU2318517C2 (zh)
SI (1) SI1392313T1 (zh)
SK (1) SK14042003A3 (zh)
WO (1) WO2002092091A1 (zh)
ZA (1) ZA200307665B (zh)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2318649T3 (es) 2000-10-20 2009-05-01 EISAI R&D MANAGEMENT CO., LTD. Procedimiento de preparacion de derivados de 4-fenoxi quinolinas.
GB0201882D0 (en) * 2002-01-28 2002-03-13 Novartis Ag Organic compounds
AU2007201056B2 (en) * 2002-01-28 2010-06-10 Hyks-Instituutti Oy Treatment of rheumatoid arthritis using imatinib
GB0202874D0 (en) * 2002-02-07 2002-03-27 Novartis Ag Organic compounds
US20060094674A1 (en) * 2002-07-05 2006-05-04 Neel Benjamin G Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
JPWO2004080462A1 (ja) 2003-03-10 2006-06-08 エーザイ株式会社 ｃ−Ｋｉｔキナーゼ阻害剤
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
GB0311971D0 (en) * 2003-05-23 2003-06-25 Novartis Ag Organic compounds
JP4303726B2 (ja) 2003-11-11 2009-07-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウレア誘導体およびその製造方法
ES2322175T3 (es) 2004-09-17 2009-06-17 EISAI R&D MANAGEMENT CO., LTD. Composicion medicinal con estabilidad mejorada y gelificacion reducida.
US20060235006A1 (en) * 2005-04-13 2006-10-19 Lee Francis Y Combinations, methods and compositions for treating cancer
EP1925941B1 (en) * 2005-08-01 2012-11-28 Eisai R&D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
US9006240B2 (en) * 2005-08-02 2015-04-14 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
WO2007019116A1 (en) * 2005-08-03 2007-02-15 Novartis Ag Use of hdac inhibitors for the treatment of myeloma
AR057854A1 (es) * 2005-11-04 2007-12-19 Wyeth Corp Combinaciones antineoplasicas con inhibidor de mtor, herceptina y/o hki-272 (e)-n-{4-[3-cloro-4-(2-piridinilmetoxi) anilino]-3-ciano-7-etoxi-6-quinolinil}-4-(dimetilamino)-2-butenamida
KR101353763B1 (ko) * 2005-11-07 2014-01-21 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 ｃ―ｋｉｔ 키나아제 저해 물질의병용
CN104706637A (zh) 2006-05-18 2015-06-17 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
CN1899616A (zh) * 2006-07-20 2007-01-24 中国人民解放军军事医学科学院生物工程研究所 非受体酪氨酸激酶c－Abl特异性抑制剂的新用途
EP2065372B1 (en) 2006-08-28 2012-11-28 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
WO2008093855A1 (ja) * 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. 未分化型胃癌治療用組成物
EP2218712B1 (en) 2007-11-09 2015-07-01 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
BRPI0906576A2 (pt) * 2008-01-29 2015-07-07 Eisai R&D Man Co Ltd Composição farmacêutica, kit, uso de um composto, e, agente terapêutico para câncer
KR20180128078A (ko) * 2008-06-17 2018-11-30 와이어쓰 엘엘씨 Ｈｋｉ-272 및 비노렐빈을 함유하는 항신생물성 조합물
JP5898074B2 (ja) 2010-06-25 2016-04-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤
CA2828946C (en) 2011-04-18 2016-06-21 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
EP2714937B1 (en) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
WO2014185540A1 (en) 2013-05-14 2014-11-20 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
KR102329681B1 (ko) 2014-08-28 2021-11-23 에자이 알앤드디 매니지먼트 가부시키가이샤 고순도의 퀴놀린 유도체 및 이를 제조하는 방법
CA2976325C (en) 2015-02-25 2023-07-04 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
RU2729936C2 (ru) 2015-06-16 2020-08-13 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противораковое средство

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
DE3372965D1 (en) 1982-07-23 1987-09-17 Ici Plc Amide derivatives
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
GB8517360D0 (en) 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
US4978672A (en) 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
US4749713A (en) 1986-03-07 1988-06-07 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
ATE72816T1 (de) 1986-11-21 1992-03-15 Ciba Geigy Ag Neue substituierte alkandiphosphonsaeuren.
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
TW225528B (zh) 1992-04-03 1994-06-21 Ciba Geigy Ag
DE69232539T3 (de) 1992-10-28 2007-01-04 Genentech, Inc., South San Francisco Verwendung von anti-VEGF Antikörpern zur Behandlung von Krebs
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
KR100437582B1 (ko) 1995-07-06 2004-12-17 노파르티스 아게 피롤로피리미딘및그들의제조방법
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
AU2195297A (en) * 1996-02-20 1997-09-02 Sloan-Kettering Institute For Cancer Research Combinations of pkc inhibitors and therapeutic agents for treating cancers
DK0892789T4 (da) 1996-04-12 2010-04-06 Warner Lambert Co Irreversible inhibitorer af tyrosin kinaser
WO1997039135A1 (en) * 1996-04-17 1997-10-23 Board Of Regents, The University Of Texas System Enhanced expression of transgenes
WO1997049688A1 (en) 1996-06-24 1997-12-31 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
WO1998010767A2 (en) 1996-09-13 1998-03-19 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
US20020128240A1 (en) * 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US20010051628A1 (en) * 1998-05-04 2001-12-13 H.-J. Su Huang Methods to modulate the resistance of cells to apoptosis mediated by mutant epidermal growth factor receptors
AU5620299A (en) 1998-08-11 2000-03-06 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
DE69926536T3 (de) 1998-12-22 2013-09-12 Genentech, Inc. Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung
US6833373B1 (en) * 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
GB9903547D0 (en) 1999-02-16 1999-04-07 Novartis Ag Organic compounds
PT1165085E (pt) 1999-03-30 2006-10-31 Novartis Ag Derivados de ftalazina para tratar doencas inflamatorias
GB9907908D0 (en) * 1999-04-07 1999-06-02 Bataille Regis Organic compounds
GB9911582D0 (en) * 1999-05-18 1999-07-21 Pharmacia & Upjohn Spa Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound
BR0014001A (pt) * 1999-09-15 2002-05-21 American Home Prod Método de potencialização de quimioterapia e tratamento de tumores sólidos
EP2289549A3 (en) * 1999-10-01 2011-06-15 Immunogen, Inc. Immunoconjugates for treating cancer
AU778042B2 (en) * 1999-10-19 2004-11-11 Merck & Co., Inc. Tyrosine kinase inhibitors
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
AU2001294511A1 (en) * 2000-06-30 2002-01-08 The Regents Of The University Of California New strategy for leukemia therapy
AU2002211427A1 (en) * 2000-10-05 2002-04-15 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
HUP0301276A2 (hu) * 2000-10-06 2003-11-28 Biomedicines, Inc. Kombinációs terápia ösztrogénérzékeny betegségek kezelésére
HU229106B1 (en) * 2000-10-27 2013-07-29 Novartis Ag Treatment of gastrointestinal stromal tumors
AU2002308218B2 (en) * 2001-02-27 2005-11-10 Novartis Ag Combination comprising a signal transduction inhibitor and an epothilone derivative
AU2003272007A1 (en) * 2002-10-25 2004-05-13 The Administrators Of The Tulane Educational Fund Use of n-5-4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension
US8168621B2 (en) * 2005-09-30 2012-05-01 Endece, Llc 6-substituted estradiol derivatives and methods of use
TW200740776A (en) * 2006-02-06 2007-11-01 Osi Pharm Inc N-phenylbenzotriazolyl c-kit inhibitors
US20110105529A1 (en) * 2008-05-15 2011-05-05 University Of Southern California ERCC-1 Gene Expression Predicts Chemotherapy Outcome

Also Published As

Publication number Publication date
IL158274A0 (en) 2004-05-12
CN1700917B (zh) 2010-04-28
ATE359790T1 (de) 2007-05-15
US20120283206A1 (en) 2012-11-08
ZA200307665B (en) 2004-04-21
PL392652A1 (pl) 2010-12-06
CO5540315A2 (es) 2005-07-29
NZ529145A (en) 2005-07-29
KR20030094415A (ko) 2003-12-11
JP2010059202A (ja) 2010-03-18
CZ299756B6 (cs) 2008-11-12
EP1392313B1 (en) 2007-04-18
CZ20033098A3 (cs) 2004-02-18
PL368068A1 (en) 2005-03-21
US20040167134A1 (en) 2004-08-26
KR20080091866A (ko) 2008-10-14
WO2002092091A1 (en) 2002-11-21
RU2003135786A (ru) 2005-02-27
SK14042003A3 (sk) 2004-05-04
EP2253319A1 (en) 2010-11-24
DK1392313T3 (da) 2007-06-25
AU2002342335B2 (en) 2006-02-02
NO325453B1 (no) 2008-05-05
RU2318517C2 (ru) 2008-03-10
CA2444867A1 (en) 2002-11-21
DE60219617T2 (de) 2008-01-03
NO20034713D0 (no) 2003-10-21
EP1392313A1 (en) 2004-03-03
JP4477303B2 (ja) 2010-06-09
HUP0400038A3 (en) 2007-05-29
JP2004531549A (ja) 2004-10-14
HUP0400038A2 (hu) 2004-04-28
CA2444867C (en) 2010-08-17
CN1700917A (zh) 2005-11-23
PT1392313E (pt) 2007-07-17
NO20034713L (no) 2003-10-21
NO20076323L (no) 2007-12-07
DE60219617D1 (de) 2007-05-31
BR0209647A (pt) 2004-07-27
US20090202541A1 (en) 2009-08-13
MXPA03010401A (es) 2004-03-09
SI1392313T1 (sl) 2007-08-31
ES2283570T3 (es) 2007-11-01
ECSP034823A (es) 2003-12-24

Similar Documents

Publication Publication Date Title
HK1062895A1 (en) Combination comprising N-ä5-Ä4-(4-methyl-piperazino-methyl)-benzoylamidoÜ-2-methylphenylü-4-(3-pyridyl)-2pyrimidine-amine and a biphosphonate
TNSN06182A1 (en) COMBINATION OF (a) N-{5-[4-(4-METHYL-PYPERAZINO-METHYL)-BENZOYLAMIDO] -2-METHYLPHENYL} -4-(3-PYRIDIL)-2-PYRIMIDINE-AMINE AND (b) AT LEAST ONE HYPUSINATION INHIBITOR AND USE THEREOF
HUP0201600A2 (en) Use of antibodies against cd20 for the treatment of the graft versus host disease
NO20052927L (no) 2,4,6-trisubstituerte pyrimidiner av fosfotidylinositol (PI) 3-kinaseinhibitorer og deres anvendelse ved behandling av kreft
AU7621801A (en) Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
HU0102039D0 (en) Use of paclitaxel stabilized with albumin for the preparation of pharmaceutical compositions treating solid tumors and the pharmaceutical compositions obtained thereby
EE05507B1 (et) Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks
AR053984A1 (es) Combinacion de un inhibidor de proteina cinasa src y un inhibidor bcr - abl para el tratamiento de enfermedades proliferativas
AU7532601A (en) Materials and methods for the treatment of gastroesophageal reflux disease
PL363967A1 (en) Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
AU2003259521A1 (en) Combination of a) n-{5-(4-(4-methyl-piperazino-methyl)-benzoylamido)-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and b) a histone deacetylase inhibitor for the treatment of leukemia
AU2003233946A8 (en) 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl)-benzamide for treating ang ii-mediated diseases
HUP0303261A3 (en) Carbamate compounds for use in preventing or treating bipolar disorder
RS50148B (sr) Upotreba docetaksela za lečenje hepatoćelijskog karcinoma
DE60112581D1 (de) Zusammensetzungen zur behandlung baktrieller infektionen, welche ein oxazolidinonderivat, sulbactam und ampicillin enthalten
EP1704863A3 (en) Combination comprising N-5-4-(4-Methyl-Piperazino-Methyl-)Benzoyla Mido]-2-Methylphenyl -4-(3-Pyridyl)-2Phyrimidine-amine and a chemotherapeutic agent
ATE352307T1 (de) Zusammensetzung zur behandlung von tumoren oder krebs, welche fluorouracil und ein methylol übertragungsmittel enthält
NO20026032D0 (no) Farnesyltransferasehemmende 1,2-annelert kinolinenantiomer
FR2800614B1 (fr) Composition pour le traitement des infections des voies respiratoires
WO2006136391A3 (en) Treatment of solid tumor disease with combinations comprising imatinib and an efflux pump inhibitor
EE04524B1 (et) S-nitrosotioolid kui ained vereringeh„irete raviks
RU2001102144A (ru) Способ лечения лимфареи при эндопротезировании крупных суставов
ZA200307471B (en) Carbamate compounds for use in preventing or treating bipolar disorder.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110515